Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Eliem Therapeutics, Inc. ELYM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Eliem Therapeutics, Inc. (ELYM) is a Biotechnology company in the Healthcare sector, currently trading at $5.11. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $60M (loss), growing at -22.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $541,000 against $160M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 15.16 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $168M.

Analyst outlook: 2 / 4 analysts rate ELYM as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

ELYM SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ELYM

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ELYM: +0%/yr revenue is, -22.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ELYM: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 15.16 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ELYM: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 2 / 4 analysts rate ELYM as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.35-11.55
Volume802.69K
Avg Volume (30D)519.72K
Market Cap$342.68M
Beta (1Y)-0.38
Share Statistics
EPS (TTM)-0.88
Shares Outstanding$67.81M
IPO Date2021-08-10
Employees9
CEOAoife M. Brennan BAO, BCh, MB, MMSc
Financial Highlights & Ratios
EBITDA$-67.88M
Net Income$-59.85M
Operating Income$-67.88M
Total Cash$101.08M
Total Debt$541K
Net Debt$-35.14M
Total Assets$167.74M
Price / Earnings (P/E)-5.8
Analyst Forecast
Rating ConsensusBuy
Analysts Covering4
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS28658R1068

Price Chart

Track all markets on TradingView
ELYM
Eliem Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.35 52WK RANGE 11.55

People Also View

PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 PRDS
PRDS
Pardes Biosciences, Inc.
$2.18
+0.93%
 PEPG
PEPG
PepGen Inc.
$1.69
+0.59%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message